| Literature DB >> 34876174 |
Daniel J Hellenbrand1, Charles M Quinn1, Zachariah J Piper1, Carolyn N Morehouse1, Jordyn A Fixel1, Amgad S Hanna2.
Abstract
Traumatic spinal cord injury (SCI) is a devastating neurological condition that results in a loss of motor and sensory function. Although extensive research to develop treatments for SCI has been performed, to date, none of these treatments have produced a meaningful amount of functional recovery after injury. The primary injury is caused by the initial trauma to the spinal cord and results in ischemia, oxidative damage, edema, and glutamate excitotoxicity. This process initiates a secondary injury cascade, which starts just a few hours post-injury and may continue for more than 6 months, leading to additional cell death and spinal cord damage. Inflammation after SCI is complex and driven by a diverse set of cells and signaling molecules. In this review, we utilize an extensive literature survey to develop the timeline of local immune cell and cytokine behavior after SCI in rodent models. We discuss the precise functional roles of several key cytokines and their effects on a variety of cell types involved in the secondary injury cascade. Furthermore, variations in the inflammatory response between rats and mice are highlighted. Since current SCI treatment options do not successfully initiate functional recovery or axonal regeneration, identifying the specific mechanisms attributed to secondary injury is critical. With a more thorough understanding of the complex SCI pathophysiology, effective therapeutic targets with realistic timelines for intervention may be established to successfully attenuate secondary damage.Entities:
Keywords: Astrocytes; Cytokines; Inflammation; Macrophages; Microglia; Secondary cascade; Spinal cord injury
Mesh:
Substances:
Year: 2021 PMID: 34876174 PMCID: PMC8653609 DOI: 10.1186/s12974-021-02337-2
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Fig. 1Flowchart displaying how articles were screened to be analyzed for assessing cytokine/chemokine regulation after SCI. All studies used were performed in rats and mice and assessed local cytokine/chemokine regulation at specific times post-injury compared to uninjured or sham controls
Cytokines and chemokines involved in inflammation after SCI
| Names | Cells that secrete the cytokine/chemokine, receptors they bind to, and their effects after SCI |
|---|---|
IL-1α | Released via activated microglia and PDMs largely in response to disease, infection, or inflammatory events [ Binds to IL-1R1 [ Required for neutrophil recruitment during cell death-induced sterile inflammation [ |
IL-1β | Produced by activated microglia and PDMs as a proprotein, which is proteolytically processed to its active form by caspase 1 (CASP1/ICE) [ Binds to the IL-1R [ Plays a more substantial role than IL-1α post-SCI [ Stimulates inflammatory mediators including prostaglandins, cyclooxygenase 2, and phospholipase A2 [ |
| IL-2 | Produced by activated T-cells [ Binds to IL-2R complex, which consists of IL-2Rα, IL-2Rβ, and the common γ-chain subunits [ Contributes to the proliferation of T-helpers [ Responsible for initiating the proper response of memory T-cells to invading pathogens [ |
| IL-4 | Produced by T-helper cells, eosinophils, basophils, and mast cells [ Binds to IL-4Rɑ, which will either dimerize with the common cytokine-receptor γ-chain and produce the type-1 signaling complex, or with IL-13Rα1 and produce the type-2 signaling complex [ Increases microglia/macrophages expressing antigens characteristic of an anti-inflammatory M2 phenotype [ Increases the number of oligodendrocytes and neuronal markers βIII-tubulin and NeuN after SCI, suggesting a role in neuroprotection [ |
| IL-5 | Produced by hematopoietic and non-hematopoietic cells, including granulocytes, T-cells, and natural helper cells [ Binds to IL-5R and stimulates B-cell growth as well as increases immunoglobulin secretion (primarily IgA). Is also a key mediator in eosinophil activation [ |
| IL-6 | Expressed in astrocytes, microglia and PDMs, and neurons [ Binds to IL-6R, which exists either as a membrane-bound receptor or a soluble receptor [ Activates inflammation and is a strong recruiter of immune cells after SCI [ Acts on neural stem cells to induce their differentiation into astrocytes [ |
IL-8 | Produced by a wide variety of cells including monocytes, endothelial cells, T-cells, and macrophages [ Binds to CXCR1 and CXCR2 receptors [ Induces chemotaxis in neutrophils and granulocytes [ Upregulated for at least 14 days after SCI and strongly correlates with the extent of injury [ |
| IL-10 | Produced by monocytes, B-cells, dendritic cells, natural killer cells, and T-cells [ Binds to IL-10R heterotetramer complex made of two IL-10R1 molecules and two IL-10R2 molecules [ Downregulates several pro-inflammatory cytokines and inflammatory species [ Provides trophic support to neurons through downregulation of pro-apoptotic factors and upregulation of anti-apoptotic factors [ |
IL-12 | Produced by dendritic cells, macrophages, monocytes, neutrophils, microglia cells, and B-cells [ Binds to IL-12R, which consists of the IL-12Rβ1 and IL-12Rβ2 chains [ IL-12(p70) expresses nitric oxide synthase and TNFα in microglia and PDMs [ |
| IL-13 | Produced by T-cells, dendritic cells, and activated Th2 cells [ Binds either to IL-13Rɑ1 or IL-13Rɑ2 [ Involved in the production of transforming growth factor beta (TGF-β) [ |
IL-17ɑ | Produced by several types of cells including T-cells, dendritic cells, and macrophages [ Binds to the A and C subunits of IL-17R [ IL-17 knockout mice showed increased locomotor function after SCI suggesting a role in regulating secondary degeneration of neural tissue [ |
TNF-ɑ | Produced by microglia, PDMs, astrocytes, oligodendrocytes, monocytes, and neurons [ Two active forms are transmembrane TNFɑ and soluble TNFɑ [ Soluble TNFα is released by regulated cleavage of transmembrane TNFɑ by TNFɑ-converting enzyme (TACE/ADAM17) [ Binds to TNFR1 and TNFR2 [ Affects cell proliferation, differentiation, apoptosis, immunity, and inflammation [ Recruits macrophages to injury site [ |
| IFN-γ | Produced by γẟ T-cells and leads to the activation of macrophages [ Induces secretion of IL-10 from microglia and PDMs [ Can act synergistically with GM-CSF to promote the production of cytokines [ |
GM-CSF | Produced by macrophages, mast cells, T-cells, fibroblasts, and endothelial cells in response to immune activation and cytokines that mediate inflammation [ Causes differentiation of hematopoietic progenitor cells into granulocytes, macrophages, and dendritic cells [ Can stimulate the proliferation of bone marrow stem cells and reduce leukocyte apoptosis, as well as cause microglia to proliferate and change their morphology [ GM-CSF-induced activation of microglia may promote functional recovery and axonal regeneration by release of brain-derived neurotrophic factor or by phagocytosis of myelin debris [ |
MCP-1 | Secreted by activated T-cells, astrocytes, microglia, and monocytes [ Binds to CCR2 [ Activates and recruits mononuclear phagocytes, T-cells, and B-cells [ |
MIP-1ɑ | Secreted by activated T-cells, astrocytes, microglia, and monocytes [ Promotes chemotaxis of monocytes and T-cells [ Expression induced by pro-inflammatory stimulators, such as LPS, TNFα and IL-1β, and neuronal injury [ Can enhance the production of other pro-inflammatory cytokines via CCR1, CCR4, and CCR5 [ Impacts CNS inflammation through regulation of macrophages and astrocytes [ |
RANTES | Produced by astrocytes and is primarily involved in promoting migration of M2 macrophages [ Expression induced by IL-1 and macrophage migration inhibitory factor [ Binds to CCR1, CCR3, and CCR5 [ Associated with T-cell activation in SCI. Chronic T-cell activation subsequently contributes to neurodegeneration and inhibits repair of injured tissues [ Induces the migration and recruitment of a wide variety of cells including T-cells, dendritic cells, natural killer cells, eosinophils, basophils, mast cells, and endothelial progenitor cells [ May help amplify inflammatory response by facilitating the recruitment of inflammatory cells to the injury [ |
| TGF-β1 | Produced by lymphocytes, macrophages, and dendritic cells [ Binds to TGF-βR1, TGF-βR2, and TGF-βR3 [ Activates glial cells and phagocytes to form connective tissue and extracellular matrix [ Influences the differentiation, proliferation, and state of activation of leukocytes [ Known to suppress expression of MHC class II antigen [ |
Fig. 2Depiction of cytokine regulation following SCI in rodent models. A literature search was conducted and relevant data regarding significant cytokine regulation was collected at various timepoints. Data is presented as a percentage of studies that found significant changes in cytokine protein or mRNA expression levels compared to sham or naïve controls (p < 0.05). The number of papers used for each timepoint is listed at the top of each bar. A Changes in IL-1β levels after SCI [17, 21, 37, 38, 40–43, 45–47, 66–68, 85, 87–89, 94, 106, 107, 169–187]. The proinflammatory cytokine IL-1β shows consistent upregulation in the acute phase following SCI. However, there are some discrepancies as to whether IL-1β remains upregulated several days after injury and the second surge 14 days was only observed in mice. B Changes in TNFɑ levels after SCI [17, 36–42, 45–48, 66–69, 85, 87–89, 94–96, 107, 121, 169–180, 182–189]. The majority of studies show an upregulation of the proinflammatory cytokine TNFɑ immediately following SCI and persisting several days after injury. C Changes in IL-6 levels after SCI [17, 37, 38, 40–42, 45, 47, 66–68, 84, 85, 87–90, 93, 95, 96, 107, 121, 173, 174, 176, 178, 183, 184, 186–189]. Consistent upregulation of the proinflammatory cytokine is seen in the first 24 h following injury before returning to baseline levels by 7-day post-injury. D Changes in IL-1ɑ levels after SCI [17, 38, 40, 66, 84, 87, 90, 95]. The proinflammatory cytokine IL-1ɑ is upregulated in a similar manner to its isoform IL-1β, though IL-1β plays a more significant role following SCI [132, 133]. E Changes in IFN-γ levels after SCI [17, 38, 48, 87, 90, 95]. The relative change in IFN-γ expression following SCI remains controversial, as shown by the conflicting data presented. It appears to be upregulated in mice and downregulated in rats after 24 h. F Changes in MCP-1 levels after SCI [17, 38, 47, 84, 85, 87–90, 93, 121]. While there is some debate surrounding the regulation of the MCP-1 chemokine immediately after injury (1 h to < 6 h), nearly all data collected shows that MCP-1 expression levels elevate quickly and remain upregulated for several days. G Changes in IL-10 levels after SCI [17, 21, 38, 46, 47, 66, 85, 87–90, 96, 170, 173–176]. A delayed response is seen with IL-10 showing mixed results until upregulation at 3–7 days after injury. The anti-inflammatory cytokine returns to baseline levels by 14 days. H Changes in IL-4 levels after SCI [7, 17, 38, 47, 48, 66, 70, 87]. While some studies show increased expression of the anti-inflammatory IL-4, most researchers did not observe a change in IL-4 levels. I Changes in IL-13 levels after SCI [17, 38, 47, 48, 87, 90]. Previous studies display conflicting data surrounding the regulation of IL-13 after injury, where it was upregulated in mice and downregulated in rats 3 days hours post-injury
Fig. 3Line graph displaying the percentage of studies that observed significant upregulation in IL-1β, TNFα, IL-6, and IL-10. The majority of investigators observe a significant upregulation of the three most investigated inflammatory cytokines early after injury and TNFα and IL-1β remain upregulated. The anti-inflammatory cytokine IL-10 lags further behind and the majority of investigators show it peaking around 1-week post-injury
Fig. 4Primary injury after SCI causes cell membrane disruption and rupture of blood vessels leading to secondary injury with extensive upregulation of cytokines/chemokines and infiltration of immune cells. Microglia, the resident macrophages, are early responders and become indistinguishable in terms of morphology from peripherally derived macrophages. In rats, neutrophils peak early in the injury at around 24 h and gradually decrease over the next 7–10 days, while lymphocytes peak at lower levels and at a much later time. Pericytes also infiltrate later and interact with microglia around the edges of the injury and this entire injury site is encased by activated astrocytes
Fig. 5Diagram displaying cellular activation/infiltration after rat SCI. After the primary insult, there is a much larger secondary injury with extensive infiltration of immune cells. Neutrophil infiltration peaks 24-h post-injury and decreases over the next week. Infiltrating lymphocytes accumulate around blood vessels in gray matter as early as 6 h and T-cell specific lymphocytes peak around 9-day post-injury. Microglia are activated, retracting their cytoplasmic processes and becoming indistinguishable in terms of morphology from the infiltrating PDMs. The astrocytes also become reactive and retract the cytoplasmic processes and migrate to the lesion. Although initially the astrocytes aid in tissue repair, they eventually become scar-forming astrocytes and begin to wall off the ensuing inflammation. The final glial scar is compartmentalized with infiltrating immune cells in the center, microglia interacting with pericytes around the edges, and astrocytes encapsulating the entire tissue containing the inflammatory cells